使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon. Thank you for joining us to discuss LifeMD Inc fourth-quarter and full-year 2024 earnings results. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question-and-answer session.
各位下午好。感謝各位參與我們的會議,一同討論 LifeMD Inc 2024 年第四季及全年財報結果。今天與會者包括董事長兼執行長 Justin Schreiber,以及財務長 Marc Benathen。在管理層預先準備的發言結束後,我們將開放問答環節。
Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause actual results to differ materially from those projected.
在開始之前,我想提醒各位,本次電話會議中公司將發表若干前瞻性陳述;這些陳述受到多項風險與不確定性影響,可能導致實際結果與預期存在重大差異。
These risks and uncertainties are described in the company's 10-K and 10-Q filings and within other filings that LifeMD may make with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, March 10, 2025. The company assumes no obligation to update or revise any forward-looking statements after today's call except as required by law.
這些風險與不確定性已在公司提交的 10-K 與 10-Q 文件,以及 LifeMD 不時向美國證券交易委員會(SEC)提交的其他文件中加以說明。本次電話會議中所作的前瞻性陳述係基於公司截至今日(2025 年 3 月 10 日)可取得的現有資訊。除法律要求外,公司在今日會議後不承擔更新或修訂任何前瞻性陳述之義務。
Also, please note that management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today.
另外請注意,管理層將討論若干非 GAAP 財務衡量指標,公司認為這些指標對評估 LifeMD 的經營表現相當重要。關於這些非 GAAP 指標與最可比 GAAP 指標之間的關係及其調節表(reconciliations),可參閱公司今日稍早發布的新聞稿。
Finally, I would like to remind everyone that today's call is being recorded and will be available for replay in the Investor Relations section of the company's website.
最後提醒各位,今天的電話會議將被錄音,並將於公司網站「投資人關係」專區提供重播。
I'd now like to turn the call over to LifeMD CEO, Justin Schreiber. Please go ahead, sir.
接下來我想把電話交給 LifeMD 執行長 Justin Schreiber。先生,請開始。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Thank you, and good afternoon, everyone. After the market closed, we issued an 8-K which contained a press release announcing our fourth-quarter financial results and posted an updated corporate presentation on our website at ir.lifemd.com.
謝謝,各位下午好。在收盤後,我們提交了一份 8-K,其中包含一則新聞稿,公告我們第四季財務結果,並在 ir.lifemd.com 網站上發布了更新後的公司簡報。
LifeMD produced tremendous results in the fourth quarter that well exceeded our prior guidance, capping off a very strong 2024. Our record financial performance was driven by growth and increasing profitability in both our RexMD and LifeMD platforms. For the quarter, our telehealth revenue grew by 60% while our telehealth adjusted EBITDA grew by nearly five-fold.
LifeMD 在第四季取得了非常亮眼的成果,遠超過我們先前的指引,為表現強勁的 2024 年畫下句點。我們創紀錄的財務表現,來自 RexMD 與 LifeMD 兩大平台的成長與獲利能力提升。就本季而言,我們的遠距醫療營收成長 60%,而遠距醫療調整後 EBITDA 幾乎成長近五倍。
WorkSimpli also rebounded significantly, generating more than $1 million of adjusted EBITDA each month during the quarter, consistent with our prior guidance. In addition to these strong results, we also executed several key product launches that I expect will be critical drivers of our business in the years to come. Including the successful launch of our male hormone replacement therapy business, the launch of our nationwide pharmacy which is already licensed in 47 states, and the continued expansion of our medical and pharmacy benefits infrastructure.
WorkSimpli 也顯著回升,在本季期間每個月均產生超過 100 萬美元的調整後 EBITDA,符合我們先前的指引。除了這些強勁成果之外,我們也執行了數項關鍵產品上市,我預期這些將在未來數年成為推動業務的重要動能。其中包括我們男性荷爾蒙替代療法業務的成功推出、我們全國性藥局的上線(目前已在 47 個州取得執照),以及持續擴充我們的醫療與藥局給付(benefits)基礎設施。
2025 will be a critical year in our evolution as a leader in virtual primary care. We expect to expand our existing capabilities as well as extend our reach into new, complementary areas designed to further differentiate LifeMD as a leading provider of the highest quality and most comprehensive virtual first healthcare.
2025 年將是我們作為虛擬基層醫療領導者演進過程中的關鍵一年。我們預期將擴大既有能力,同時延伸至新的互補領域,以進一步強化 LifeMD 作為提供最高品質且最全面「虛擬優先」(virtual first)醫療照護之領先供應商的差異化優勢。
We have three strategic priorities for our business in 2025. One, solidify and grow our market-leading position in delivering comprehensive weight loss and metabolic care, including affordable access to prescription GLP-1 medications. Two, build on the early success of our hormone replacement therapy offering we launched in 2024 on our RexMD platform. Three, launch our LifeMDPlus membership program and several new high-value care offerings on our virtual primary care platform. And four, continue to grow our government and private payer programs, as well as our electronic benefit verification and prior authorization infrastructure to drive more affordable access to virtual care and prescription medications.
我們在 2025 年有三項策略重點。第一,鞏固並擴大我們在提供全面減重與代謝照護方面的市場領先地位,包括以可負擔的方式取得處方 GLP-1 藥物。第二,延續並擴大我們於 2024 年在 RexMD 平台推出之荷爾蒙替代療法服務的初期成功。第三,推出 LifeMDPlus 會員計畫,並在我們的虛擬基層醫療平台上推出數項高價值照護服務。第四,持續成長我們的政府與民間支付方(payer)方案,以及擴充我們的電子給付資格驗證與事前授權(prior authorization)基礎設施,以推動更可負擔的虛擬照護與處方藥物取得。
We are very proud of the weight loss and metabolic health program that we've built on our virtual primary care platform. This program had more than 75,000 active patients as of year-end and is well positioned for long-term growth, even as market dynamics change. Despite the FDA's recent decisions to remove semaglutide and tirzepatide from the drug shortage list, LifeMD remains extremely well positioned to benefit long term in the weight management market.
我們對於在虛擬基層醫療平台上打造的減重與代謝健康計畫深感自豪。截至年底,該計畫的活躍患者超過 75,000 人,即使市場動態改變,仍具備長期成長的良好定位。儘管 FDA 近期決定將 semaglutide 與 tirzepatide 自藥品短缺清單中移除,LifeMD 仍然具備在體重管理市場中長期受益的極佳條件。
Our focus has been and remains on providing affordable access to comprehensive obesity care and the ongoing management of clinically appropriate GLP-1 and other generic drugs that can support our patients on their journey to better metabolic health. Importantly, over 85% of our weight management revenue is related to the delivery of care. Helping patients use private insurance to access weight loss medications has been a fundamental part of our service offering since it launched in 2023. While helping patients access branded GLP-1 therapies was previously difficult due to supply shortages and lower levels of payer coverage, we are seeing several encouraging trends that cause us to be very optimistic.
我們一直以來、也將持續專注於:以可負擔的方式提供全面的肥胖症照護,以及對臨床上適用的 GLP-1 與其他學名藥進行持續管理,協助患者在改善代謝健康的旅程中獲得支持。重要的是,我們體重管理業務超過 85% 的營收與照護服務的提供相關。自 2023 年服務推出以來,協助患者使用私人保險取得減重藥物,一直是我們服務內容的核心部分。過去由於供應短缺與支付方涵蓋率較低,協助患者取得品牌 GLP-1 療法較為困難;但我們正看到幾項令人鼓舞的趨勢,使我們對前景非常樂觀。
Firstly, we're seeing a significant increase in patients getting affordable private insurance coverage for branded GLP-1 medications, especially for Zepbound. We believe this is partly due to private payer and employer coverage rates improving and to improvements we have made to our electronic benefits and prior authorization processes and overall infrastructure at LifeMD.
第一,我們看到獲得品牌 GLP-1 藥物之可負擔私人保險給付的患者顯著增加,尤其是 Zepbound。我們認為,這部分是因為民間支付方與雇主的給付涵蓋率提升,也部分來自我們在 LifeMD 對電子給付與事前授權流程,以及整體基礎設施所做的改善。
For Zepbound, we've seen an 18-percentage-point increase in the approval rate between October and January, with Zepbound prior authorization approval rates approaching 60% over the past several months. We recently announced an integration with LillyDirect's pharmacy partner, GiftHealth, to make it easier for patients who don't have insurance coverage to purchase, where appropriate, more affordable cash pay via Zepbound.
以 Zepbound 而言,我們看到其核准率在 10 月到 1 月間提升了 18 個百分點;過去幾個月 Zepbound 的事前授權核准率已接近 60%。我們近期也宣布與 LillyDirect 的藥局合作夥伴 GiftHealth 進行整合,讓沒有保險給付的患者在適當情況下,能更容易透過 Zepbound 以更可負擔的自費方式購買。
Secondly, we have seen the drug manufacturers that control the current GLP-1 market begin to compete with each other in the self-pay market now that supply levels have stabilized. In the past several weeks, both Eli Lilly and Novo Nordisk, the manufacturers of Zepbound and Wegovy, respectfully announced price reductions to their self-paid GLP-1 product offerings, bringing the price of some dose levels as low as $349 per month (technical difficulty) to reduce the price of GLP-1 medications as a result of novel and possibly more efficacious therapies coming to market and pressure from government agencies, including the FDA to care about broad access to this class of drugs.
第二,隨著供應水準趨於穩定,我們看到掌控目前 GLP-1 市場的藥廠開始在自費市場彼此競爭。在過去幾週,Zepbound 與 Wegovy 的製造商 Eli Lilly 與 Novo Nordisk 分別宣布下調其自費 GLP-1 產品方案價格,使部分劑量等級的價格低至每月 349 美元(技術問題);此舉旨在因應新型且可能更具療效的療法進入市場,以及包括 FDA 在內的政府機構施壓,要求重視此類藥物的廣泛可及性,從而降低 GLP-1 藥物價格。
As we've said repeatedly and we'll say again today for emphasis, expanded coverage for branded GLP-1 therapies is a great thing for LifeMD, our patients, and our shareholders as it results in our programs being more affordable, which enables better compliance, patient outcomes, and retention rates for our programs.
正如我們一再強調、今天也再次重申,品牌 GLP-1 療法的給付擴大,對 LifeMD、我們的患者以及股東而言都是好事;因為這會使我們的方案更可負擔,進而提升用藥遵從性、患者療效與方案留存率。
We are also very excited about our fee-for-service Medicare offerings that we'll be launching next month. We've been working on the compliance and operational infrastructure for this launch for the past two years and believe that it will be a big growth driver, not only for our weight management offering but also for our broader virtual primary care offerings.
我們也對將於下個月推出的按次計費(fee-for-service)Medicare 服務感到非常振奮。過去兩年我們一直為此次上線建置合規與營運基礎設施,並相信這將成為重要的成長動能,不僅推動我們的體重管理服務,也將帶動更廣泛的虛擬基層醫療服務。
There are approximately 24.5 million Medicare beneficiaries enrolled in stand-alone prescription drug plans, and a substantial number of conditions like obesity and type 2 diabetes that could make them candidates for GLP-1 receptor agonist medications. Although part D coverage for GLP-1 drugs currently requires certain comorbidities, we are optimistic that Medicare will begin covering these medications for obesity. And we aim to make LifeMD the easiest and most affordable way for this population to access comprehensive obesity care and these medications once coverage is available.
約有 2,450 萬名 Medicare 受益人參加獨立的處方藥計畫,而肥胖症與第二型糖尿病等多種疾病的患者人數相當可觀,可能使其成為 GLP-1 受體致效劑藥物的適用對象。儘管目前 GLP-1 藥物的 Part D 給付仍要求具備特定共病,我們仍樂觀認為 Medicare 將開始為肥胖症給付這些藥物。一旦給付到位,我們的目標是讓 LifeMD 成為此族群取得全面肥胖症照護與這些藥物最容易、也最可負擔的方式。
It's important to note that in addition to GLP-1 therapies, LifeMD also offers exceptionally affordable, stand-alone and combination generic medications that can support patients with weight loss, including the triple therapy we announced last September.
需要注意的是,除了 GLP-1 療法之外,LifeMD 也提供價格極具競爭力的單方與複方學名藥,可協助患者減重,其中包括我們於去年 9 月宣布的三聯療法。
As we collect more data, we are optimistic on the efficacy profile of these medications and believe that they will play an important part in our weight management offerings in the future, especially if access to personalized versions of GLP-1 therapy becomes more difficult for patients who do not have insurance coverage.
隨著我們蒐集更多數據,我們對這些藥物的療效表現抱持樂觀,並相信它們未來將在我們的體重管理產品組合中扮演重要角色,尤其是在未投保的患者取得個人化版本 GLP-1 療法的難度提高時。
Lastly, the GLP-1-supported weight loss market has become highly fragmented, with hundreds if not thousands of smaller players providing varying quality offerings, many of which rely exclusively on compounded drugs from less reputable sources and async-only care. We believe many, if not, most of these market participants, will struggle to adapt in this changing environment, which has the potential to reduce acquisition costs and expand the overall market for companies like LifeMD.
最後,GLP-1 支持的減重市場已變得高度分散,數以百計甚至數以千計的小型業者提供品質不一的服務,其中許多業者完全依賴來自較不具聲譽來源的配製藥物以及僅提供非同步照護。我們認為,許多(即使不是大多數)市場參與者將難以在這個變動的環境中調整,這有可能降低獲客成本,並擴大像 LifeMD 這類公司的整體市場。
Now let's move on to RexMD. Since launching in December 2019, RexMD has rapidly become one of the leading men's health brands in the country. While this business was almost entirely sexual-health driven when it launched, today, we have expanded the reach of this brand to include multiple areas of sexual health, weight management, hair loss, insomnia, and most recently, hormone replacement therapy, or HRT.
接下來我們談 RexMD。自 2019 年 12 月推出以來,RexMD 已迅速成為全國領先的男性健康品牌之一。該業務在推出時幾乎完全由性健康驅動,但如今我們已擴大品牌觸及範圍,涵蓋性健康的多個領域、體重管理、掉髮、失眠,以及最近的荷爾蒙替代療法(HRT)。
RexMD currently produces over $80 million in annualized revenue, and we expect to see 15% to 20% growth in 2025, driven by the continued growth of our leading sexual health offerings and rapid expansion into our newly launched HRT offering. Today, RexMD has over 175,000 active patient subscribers, and we expect this number to continue to increase with the growth of our HRT program and other new clinical areas we expand into.
RexMD 目前的年化營收超過 8,000 萬美元,我們預期 2025 年將成長 15% 至 20%,成長動能來自我們領先的性健康產品持續成長,以及新推出的 HRT 服務快速擴張。目前 RexMD 擁有超過 175,000 名活躍訂閱患者,我們預期隨著 HRT 計畫與其他新臨床領域的拓展,該數字將持續增加。
Building capabilities and infrastructure that can differentiate LifeMD, create better experiences and outcomes for our patients, and increase the bottom line for our shareholders was a major priority in 2024 and will continue to be a focus in 2025. Two of the most important investments we made, which we believe will play a major role in our future success, were the launch of our 50-state commercial pharmacy and the investments we made in contracting with private and government payers.
建立能夠使 LifeMD 脫穎而出的能力與基礎設施、為患者創造更佳體驗與結果,並提升股東獲利,是 2024 年的重要優先事項,且在 2025 年仍將是重點。我們所做的兩項最重要投資(我們相信將在未來成功中扮演關鍵角色)是:推出我們覆蓋 50 州的商業藥局,以及在與民間與政府支付方簽約方面的投資。
In late 2024, we announced the launch of our first dedicated LifeMD pharmacy. I am pleased to announce that as of today, this pharmacy is licensed in 47 states and is shipping approximately 20,000 orders per month. We remain on track to realize the previously disclosed $5 million of annual economic benefits from the pharmacy by the end of 2026.
在 2024 年底,我們宣布推出第一家 LifeMD 專屬藥局。我很高興宣布,截至今日,該藥局已在 47 個州取得執照,且每月出貨約 20,000 筆訂單。我們仍按計畫在 2026 年底前,實現先前揭露的藥局每年 500 萬美元經濟效益。
While today the LifeMD pharmacy is solely focused on prescription shipments for our lifestyle healthcare business, we are in the process of building out non-sterile compounding capabilities that we expect to be operational in the next four to six months. This will be a huge advancement for LifeMD that will enable us to expand our portfolio of personalized and affordable therapies in areas such as men's and women's HRT, sexual health, dermatology, and more.
目前 LifeMD 藥局僅專注於我們生活型態醫療業務的處方出貨,但我們正在建置非無菌配製能力,預期在未來四到六個月內投入營運。這將是 LifeMD 的重大進展,使我們能在男性與女性 HRT、性健康、皮膚科等領域,擴大個人化且可負擔的療法產品組合。
We continue to advance our insurance offerings at a measured pace and today are enrolled with private payers in 20 states. As I mentioned, our Medicare program remains on track for launch in April, and we expect this will become a significant competitive advantage for LifeMD across our virtual primary platform.
我們以審慎的步調持續推進保險服務,目前已在 20 個州與民間支付方完成加入。如我所提,我們的 Medicare 計畫仍按期於 4 月推出,我們預期這將成為 LifeMD 在虛擬基層醫療平台上的重要競爭優勢。
This offering will significantly expand the addressable market for LifeMD's primary care, metabolic health, behavioral health, and prescription services. By the end of 2025, we anticipate having approximately 150 million lives under coverage.
此項服務將大幅擴大 LifeMD 在基層醫療、代謝健康、行為健康與處方服務的可服務市場。到 2025 年底,我們預期將有約 1.5 億名受保人納入保障範圍。
As a final topic, LifeMD expects to launch several new service offerings in 2025. We recently announced plans to enter the behavioral health space in the second quarter with the hire of Julian Cohen, a highly experienced senior leader. This offering is naturally synergistic with our expanded insurance capabilities, our rapidly growing therapeutic weight management offering, our sizable and growing men's health business, and soon-to-be launched women's health offering.
最後一個主題,LifeMD 預期在 2025 年推出數項新服務。我們近期宣布計畫於第二季進入行為健康領域,並聘任資深領導人 Julian Cohen,他具備豐富經驗。此項服務與我們擴大的保險能力、快速成長的治療型體重管理服務、規模可觀且持續成長的男性健康業務,以及即將推出的女性健康服務,具有天然的協同效應。
Initially, we plan to offer async-first treatment for anxiety and depression and believe there are many large markets within the behavioral health space where our asynchronous virtual primary care platform can support the delivery of much-needed behavioral health offerings.
初期我們計畫提供以非同步為優先的焦慮與憂鬱症治療,並相信在行為健康領域中存在許多大型市場,我們的非同步虛擬基層醫療平台可支援提供迫切需要的行為健康服務。
In the second quarter, we will also be launching an enhanced version of our virtual care membership program we refer to as LifeMDPlus. Our expectation is that over time, LifeMDPlus will be the backbone of everything we offer on LifeMD's virtual care platform. Initially priced at $19 per month, it will offer patients the following benefits in addition to any specialty care programs they are subscribed to: 24/7 care by LifeMD doctors and nurse practitioners, this care can be self-pay or covered by insurance, on-demand convenient prescriptions and prescription refills, access to beautifully tracked routine and specialty lab work, self-pay or covered by insurance, and a marketplace for the highest quality OTC health and wellness products.
在第二季,我們也將推出升級版的虛擬照護會員方案,我們稱之為 LifeMDPlus。我們預期隨著時間推進,LifeMDPlus 將成為 LifeMD 虛擬照護平台上所有服務的核心骨幹。初期定價為每月 19 美元,除患者所訂閱的任何專科照護方案外,還將提供以下福利:由 LifeMD 醫師與執業護理師提供 24/7 照護(可自費或由保險給付)、隨需且便利的處方開立與續配、可美觀追蹤的例行與專科檢驗(可自費或由保險給付),以及提供最高品質 OTC 健康與保健產品的市集。
Our aim is to leverage our brand equity, amazing providers, and highly differentiated care platform to create a strong value proposition around LifeMDPlus membership. We believe that this will have a meaningful, positive impact on the experience of patients on our platform, their compliance with care programs they purchase from us, and their overall health. We especially think that LifeMDPlus will play a big role in encouraging preventative healthcare and will make things like annual wellness visits, labs, and medication compliance much easier and affordable for patients.
我們的目標是運用品牌資產、卓越的醫療提供者,以及高度差異化的照護平台,打造 LifeMDPlus 會員的強大價值主張。我們相信,這將對平台患者的體驗、其對所購買照護方案的遵從性,以及整體健康狀況帶來顯著且正面的影響。我們尤其認為 LifeMDPlus 將在鼓勵預防醫療方面扮演重要角色,並讓年度健康檢查、檢驗與用藥遵從等事項對患者而言更容易且更可負擔。
In addition to behavioral health and LifeMDPlus, we expect to launch a women's health specialty offering in the second half of 2025. We plan to provide more details on this on future quarterly conference calls. In short, LifeMD is well positioned to continue to expand our role as a leading provider of differentiated virtual care in 2025 and beyond.
除行為健康與 LifeMDPlus 外,我們預期在 2025 年下半年推出女性健康專科服務。我們計畫在未來的季度電話會議中提供更多細節。總之,LifeMD 已具備良好條件,將在 2025 年及未來持續擴大我們作為差異化虛擬照護領先提供者的角色。
With that, I will now turn the call over to our CFO, Marc Benathen, to discuss fourth-quarter and full-year 2024 results. Marc?
接下來,我將把電話會議交給我們的財務長 Marc Benathen,請他說明 2024 年第四季與全年業績。Marc?
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
Thank you, Justin, and good afternoon, everyone. LifeMD achieved very strong fourth-quarter performance with consolidated revenue growing 43% versus the year-ago period to $64.3 million. Core telehealth revenue grew by 60% versus the prior year with stand-alone adjusted EBITDA profitability at $5.9 million, an increase of 396% versus prior year.
謝謝你,Justin,各位下午好。LifeMD 在第四季繳出非常強勁的表現,合併營收較去年同期成長 43% 至 6,430 萬美元。核心遠距醫療營收較去年成長 60%,單獨口徑的調整後 EBITDA 獲利為 590 萬美元,較去年增加 396%。
Telehealth subscriber growth remains strong, with the number of active subscribers increasing 27% year over year to over 275,000 at quarter end. The number of WorkSimpli active subscribers grew by 3% to 164,000. Importantly, WorkSimpli's performance stabilized in Q4 with average monthly adjusted EBITDA are returning to over $1 million as we previously guided.
遠距醫療訂閱戶成長仍然強勁,季度末活躍訂閱戶數年增 27% 至超過 275,000。WorkSimpli 的活躍訂閱戶數成長 3% 至 164,000。重要的是,WorkSimpli 的表現於第四季趨於穩定,平均每月調整後 EBITDA 正如我們先前指引,回升至超過 100 萬美元。
Gross margin for the fourth quarter was 85.3%, a decline of 280 basis points versus the prior year due to changes in revenue mix and one-time impacts related to the onboarding of a new pharmacy. We fully expect gross margin rates to return to their normalized 88% to 90% in 2025. Gross profit was $54.8 million, an increase of 39% from the year-ago period.
第四季毛利率為 85.3%,較去年下降 280 個基點,主因為營收組合變化以及與新藥局導入相關的一次性影響。我們完全預期 2025 年毛利率將回到常態化的 88% 至 90%。毛利為 5,480 萬美元,較去年同期增加 39%。
Our GAAP net loss attributable to common stockholders for the fourth quarter was $883,000 or a loss of $0.02 per share. This compares with a GAAP net loss attributable to common stockholders for the fourth quarter of 2023 of $4.5 million or a loss of $0.12 per share.
我們第四季歸屬於普通股股東的 GAAP 淨損為 88.3 萬美元,或每股虧損 0.02 美元。相較之下,2023 年第四季歸屬於普通股股東的 GAAP 淨損為 450 萬美元,或每股虧損 0.12 美元。
Adjusted EBITDA as a non-GAAP measure, we define as income or loss attributable to common shareholders before various items as outlined in today's earnings news release. Adjusted EBITDA totaled $9 million for the fourth quarter as compared with $5 million in the year-ago period.
調整後 EBITDA 作為一項非 GAAP 指標,我們將其定義為歸屬於普通股股東的收益或虧損,在扣除今日財報新聞稿所列之各項項目前的數值。第四季調整後 EBITDA 合計為 900 萬美元,較去年同期的 500 萬美元增加。
Telehealth adjusted EBITDA as a non-GAAP measure defined as adjusted EBITDA for only our telehealth business excluding WorkSimpli. This measure was $5.9 million for the fourth quarter of 2024, as compared to $1.2 million in the year-ago period. We exited the fourth quarter with $35 million in cash.
遠距醫療調整後 EBITDA 為一項非 GAAP 指標,定義為僅針對我們遠距醫療業務(不含 WorkSimpli)的調整後 EBITDA。2024 年第四季該指標為 590 萬美元,較去年同期的 120 萬美元增加。我們在第四季結束時持有 3,500 萬美元現金。
Now turning to full-year 2024 results. For 2024, consolidated revenue was $212.5 million, an increase of 39% versus 2023. Telehealth revenue grew 61% on a stand-alone basis. Growth margin for the year was 88.7%, an increase of 110 basis points versus 2023.
接著看 2024 全年業績。2024 年合併營收為 2.125 億美元,較 2023 年成長 39%。遠距醫療營收以獨立口徑計算成長 61%。全年毛利率為 88.7%,較 2023 年提高 110 個基點。
A GAAP net loss attributable to common stockholders for 2024 was $22 million or a loss of $0.53 per share. This compares with the GAAP net loss attributable to common stockholders for 2023 of $23.7 million or a loss of $0.70 per share.
2024 年歸屬於普通股股東的 GAAP 淨損為 2,200 萬美元,或每股虧損 0.53 美元。相較之下,2023 年歸屬於普通股股東的 GAAP 淨損為 2,370 萬美元,或每股虧損 0.70 美元。
Adjusted EBITDA total $14.4 million for 2024, compared with $11.2 million for 2023. Telehealth adjusted EBITDA total $7.4 million for the year, as compared with a loss of $5.2 million for 2023.
2024 年調整後 EBITDA 合計為 1,440 萬美元,較 2023 年的 1,120 萬美元增加。全年遠距醫療調整後 EBITDA 合計為 740 萬美元,相較 2023 年為虧損 520 萬美元。
Turning to financial guidance, today we are introducing guidance for 2025 consolidated revenue of $265 million to $275 million with Telehealth revenue of $205 million to $213 million. We're also introducing consolidated adjusted EBITDA guidance for 2025 of between $30 million and $32 million with Telehealth adjusted EBITDA of approximately $20 million.
接著談財務指引,今天我們首次提供 2025 年合併營收指引為 2.65 億至 2.75 億美元,其中遠距醫療營收為 2.05 億至 2.13 億美元。我們也首次提供 2025 年合併調整後 EBITDA 指引為 3,000 萬至 3,200 萬美元,其中遠距醫療調整後 EBITDA 約為 2,000 萬美元。
This wraps up our financial results. I'd now like to turn the call back over to Justin.
以上為我們的財務結果。接下來我想把電話交回給 Justin。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Thanks, Marc. 2024 was an incredible year for LifeMD, characterized by outsized performance from our telehealth offerings and the notable addition of key new capabilities, including our pharmacy and insurance offerings. The progress we made last year, coupled with continued execution against our existing businesses and planned new launches, will continue to drive our performance in 2025. I believe we have one of the most comprehensive and differentiated offerings in telehealth that continues to broaden and strengthen our capabilities as we grow.
謝謝,Marc。2024 年對 LifeMD 來說是令人驚豔的一年,特點是我們遠距醫療產品帶來超預期的表現,以及新增多項關鍵新能力,包括我們的藥局與保險服務。我們去年取得的進展,加上持續落實既有業務的執行與規劃中的新產品上市,將在 2025 年持續推動我們的表現。我相信我們擁有遠距醫療領域中最全面且差異化的產品之一,並且在成長過程中持續擴大與強化我們的能力。
With that, I'd like to open the call to Q&A. Operator?
接下來,我想開放問答。接線員?
Operator
Operator
(Operator Instructions) David Larsen, BTIG.
(接線員指示)David Larsen,BTIG。
David Larsen - Analyst
David Larsen - Analyst
Hi, congratulations on the very good quarter and the guide. Can you talk a little bit about your relationship with LillyDirect, how that will work, how do you make money, how do they make money? And then just any thoughts on Novo's program as well.
嗨,恭喜本季表現非常好以及指引。你能談談你們與 LillyDirect 的合作關係嗎?它將如何運作?你們如何賺錢?他們如何賺錢?另外也想請教對 Novo 的方案有何看法。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
So the arrangement was not with Lilly directly. It's a relationship that LifeMD has with a third-party pharmacy that LillyDirect uses to ship cash pay vials of their medications directly to patients. So LifeMD will be integrating with that third-party pharmacy. And really what it will do is enhance the experience of patients that are receiving virtual care through LifeMD that are not covered by their insurance for a branded therapy and, therefore, decide to purchase a more affordable cash pay Zepbound product directly from LillyDirect.
所以這項安排並不是直接與 Lilly 合作。這是 LifeMD 與一家第三方藥局的合作關係;LillyDirect 會使用該藥局將其藥品的自費小瓶(cash pay vials)直接寄送給病患。因此 LifeMD 將與該第三方藥局進行系統整合。實際上,這將提升透過 LifeMD 接受虛擬照護、但其保險不涵蓋品牌療法的病患體驗;因此他們會選擇直接透過 LillyDirect 購買更可負擔的自費 Zepbound 產品。
LifeMD will continue to make money, Dave (technical difficulty)
LifeMD 將會繼續賺錢,Dave(技術問題)
As far as the second question, we're generally very optimistic that manufacturers continue to lower prices as we just said on the call. We think that's a trend that has to continue. There still is a problem with coverage and affordability of these medications. And so we applaud Novo and Lilly for lowering the prices somewhat or slightly on their vials and -- or for Lilly in their vials. For Novo, it's their -- I believe their cash pay options are still using an auto injector.
至於第二個問題,我們整體上非常樂觀,因為製造商正如我們在電話會議中所說,持續降價。我們認為這是一個必須延續的趨勢。這些藥物在給付涵蓋與可負擔性方面仍然存在問題。因此,我們肯定 Novo 與 Lilly 對其小瓶產品的價格做出一定程度或小幅度的下調——或就 Lilly 而言,是針對其小瓶產品。至於 Novo,我相信他們的自費選項仍是使用自動注射器。
We're super encouraged by this. We hope it continues, obviously a big part of what we focus on at LifeMD is helping pay increasing access for patients to affordable versions of these medications along with incredible healthcare. So very encouraged by it. We don't have any relationship currently with Novo, although we expect to be able to offer Novo's cash pay products through our platform in the future.
我們對此非常受到鼓舞。我們也希望這能持續下去;顯然,LifeMD 很大一部分的重點在於協助提升病患取得這些藥物可負擔版本的可近性,同時提供卓越的醫療照護。所以我們非常受到鼓舞。我們目前與 Novo 沒有任何合作關係,但我們預期未來能透過我們的平台提供 Novo 的自費產品。
David Larsen - Analyst
David Larsen - Analyst
And then as these products come off the drug shortage list, can you talk about your ability to personalize compounded medications and what goes into that? How will you be doing that? And then how do you measure the personalization aspect like you talk about the data that you collect in the EMR, what personalization steps matter for each individual? Does lab work go into that? Just any color there would be very helpful.
另外,當這些產品從藥品短缺清單中移除後,你能談談你們客製化調劑藥(compounded medications)的能力,以及其中涉及哪些內容嗎?你們將如何進行?以及你們如何衡量你所提到的客製化面向,例如你們在 EMR 中蒐集的資料,對每位個體而言哪些客製化步驟最重要?會包含實驗室檢驗嗎?任何補充說明都會很有幫助。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
I'm not going to get into the legal aspects of personalized compounded medications for weight loss or other conditions. I think what I'd like to remind everybody of is that LifeMD is a provider of incredible virtual healthcare. Although we do have our own pharmacy, we don't use our own pharmacy for GLP-1 medications. We work with a number of the leading third-party pharmacies out there that we've vetted to ensure that they're making high-quality products.
我不會深入討論針對減重或其他病症之個人化調劑藥的法律層面。我想提醒大家的是,LifeMD 是提供卓越虛擬醫療照護的服務提供者。雖然我們有自有藥局,但我們不使用自有藥局來提供 GLP-1 藥物。我們與多家領先的第三方藥局合作,並已完成審核,以確保他們製作高品質產品。
We're going to do whatever is right, David, when it comes down to respecting the intellectual property of pharmaceutical companies, and also for our patients. So whether or not -- I think it's a little bit too early to tell exactly what many of the third-party pharmacies that we work with will do.
David,在尊重製藥公司的智慧財產權以及對病患負責這兩方面,我們會做正確的事。因此,至於是否——我認為現在要確切判斷我們合作的許多第三方藥局將會怎麼做,仍稍嫌過早。
But I do believe that many of them will be offering personalized versions of GLP-1 medications. And if it's something that, again, is not a violation of the intellectual property of pharmaceutical companies and makes sense for our patients and increases access to these medications, that's something that we'll be open to.
但我確實相信,其中許多藥局將會提供 GLP-1 藥物的個人化版本。如果這件事同樣不會侵犯製藥公司的智慧財產權,且對我們的病患有意義並能提升取得這些藥物的可近性,我們會對此保持開放態度。
Operator
Operator
Steve Dechert, KeyBanc.
Steve Dechert,KeyBanc。
Steve Dechert - Analyst
Steve Dechert - Analyst
If you continue to expand commercial insurance acceptance with additional payers and states, how much do you think this is contributing to new telehealth subscriber growth, and are you seeing a higher level of patient retention? And then as a follow-up, what kind of traction are you seeing on your non-GLP weight loss treatment option?
如果你們持續在更多付款方與州擴大商業保險的受理範圍,你認為這對遠距醫療新訂閱者成長的貢獻有多大?你們是否看到更高的病患留存率?另外追問一下,你們的非 GLP 減重治療選項目前看到什麼樣的進展?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
On the insurance, on the question related to -- I assume that was related to private payer programs, right now, we're still very focused on the infrastructure and expanding the number of lives that we have under coverage. It's important for us to reach a critical mass there before this will really enable us to drive effective conversion rates and CPAs. So right now, that business is still very small, but as we mentioned on the call, we are very optimistic about where we can get to this year.
關於保險、關於相關問題——我假設那是與私人付款方計畫有關,對吧——目前我們仍然非常專注於基礎設施,以及擴大我們納入保障的承保人數(lives)。在這真正讓我們能夠推動有效的轉換率與CPA之前,對我們而言先達到臨界規模很重要。所以目前那塊業務仍然很小,但正如我們在電話會議中提到的,我們對今年能達到的進展非常樂觀。
We think we can -- we think by the end of the year, we'll have around 150 million lives under contract between our private and government programs. And we're really excited about how that could drive the growth of the business longer term.
我們認為——我們認為到今年年底,我們在私人與政府計畫之間,合約涵蓋的承保人數大約會達到1.5億。而我們也非常興奮,這將如何在更長期推動業務成長。
Steve Dechert - Analyst
Steve Dechert - Analyst
And then just wanted to ask on the non-GLP weight loss treatment option, what kind of traction you're seeing there?
另外想請教一下,關於非GLP減重治療選項,你們目前看到的市場牽引力如何?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
So it's something that -- so we do have a non-GLP-1 weight loss offering when appropriate for patients. It's still a small business for us is the best way to answer that. But it's something that we're placing -- many of our affiliated providers are placing more emphasis on. And look, at some of these, I think it's fair to say that if GLP-1 medications become more difficult for patients to affordably access, I think you'll see that side of the business grow a lot.
是的,這件事——我們確實在適合患者的情況下,提供非GLP-1的減重方案。最好的回答方式是:對我們而言這仍是一個小型業務。但這也是我們正在加大投入的方向——我們許多合作的醫療提供者正把更多重點放在這上面。而且你看,就其中一些情況而言,我認為可以合理地說,如果GLP-1藥物變得更難讓患者以可負擔的方式取得,我想你會看到這一側的業務成長很多。
Operator
Operator
(Operator Instructions)
(接線員指示)
Brooks O'Neil, Lake Street Capital Markets.
Brooks O'Neil,Lake Street Capital Markets。
Brooks O'Neil - Analyst
Brooks O'Neil - Analyst
I'm just curious, maybe Marc could talk a little bit about the decline in the gross margin and just help us to be sure we understand what factors are driving that.
我只是好奇,也許Marc可以談談毛利率下滑的情況,並協助我們確認理解:究竟是哪些因素在驅動這個變化。
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
Yeah, absolutely. So essentially, we onboarded a new pharmacy, mostly within the weight management space. There were some upfront costs associated with that related to shipping, some inventory which we did take expense for since the intention was to sell it very rapidly. So all of that drove a one-time increase in expenditures and the cost of goods sold that we booked in the fourth quarter. That obviously normalizes going forward.
好的,當然。基本上,我們新導入了一家藥局,主要是在體重管理領域。這當中有一些前期成本,與運輸相關,還有一些庫存;由於我們的意圖是非常快速地售出,因此我們也將其列為費用。因此,這些因素在第四季推動了一次性的支出增加,以及我們入帳的銷貨成本上升。而這在未來會回歸正常。
And from a runway, we're actually seeing gross margin return back to the normal 88% to 90% levels on a consolidated basis, so it was really driven by the onboarding of this pharmacy, bringing inventory in-house, front loading a bunch of expense. We also took a fairly conservative accounting approach.
從後續趨勢來看,我們其實看到合併口徑的毛利率回到正常的88%到90%水準,所以這主要是由於導入這家藥局、把庫存納入內部、以及前置認列一大筆費用所致。我們也採取了相當保守的會計處理方式。
Brooks O'Neil - Analyst
Brooks O'Neil - Analyst
Maybe somebody could just talk about right now, given the success you've had bringing WorkSimpli back, what's your outlook for the future of that business?
也許有人可以談談,現在鑑於你們成功讓WorkSimpli重回正軌,你們對這項業務未來的展望是什麼?
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
Yeah, well, look, I mean, WorkSimpli has done a great job getting back on track. Obviously, a lot of their problems last year were self-induced. Their Founder and CEO is really taking the reins there. We've seen that business consistently growing and consistently producing circa $1 million a month in EBITDA, in some cases a little bit higher.
是的,你看,我的意思是,WorkSimpli在重回正軌方面做得非常好。顯然,他們去年很多問題是自找的。他們的創辦人兼CEO正在真正掌舵。我們看到那項業務持續成長,並且穩定產出約每月100萬美元的EBITDA,有些月份甚至略高一些。
We expect that to continue and for the business not to go back to some of the issues that they had last year which again were self-induced, poor execution of the market. That has been behind them. They re-platformed some of what they do also, which has led to improving conversion rates. And I think they're probably in the earlier stages of realizing that, so there's essentially a lot of upside for them to grow over the next couple of years that we don't get that factored in.
我們預期這會持續下去,而且該業務不會再回到去年那些問題——再次強調,那些是自找的、是市場執行不佳造成的。那些已經成為過去。他們也對部分業務進行了重新平台化(re-platform),這也帶來轉換率的改善。我認為他們可能還在開始實現這些效益的早期階段,因此在未來幾年基本上還有很大的上行空間可以成長,而我們並沒有把這點納入(預期)之中。
Brooks O'Neil - Analyst
Brooks O'Neil - Analyst
Justin, you and I talked a little bit about reimbursement for telehealth services in Medicare. Maybe you could just give us an update on where you think that stands and what the future holds for reimbursement for telehealth and Medicare.
Justin,你我之前稍微談過Medicare對遠距醫療服務的給付。也許你可以更新一下你認為目前進展到哪裡,以及未來遠距醫療與Medicare給付會如何發展。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Sure, I mean, I'm not quite sure how valuable my opinion is on this topic. But look, I think you and I both agree that Medicare has to cover these drugs, and I think it's also pretty likely that there are negotiations that have been going on for some time between Medicare and Lilly and Novo regarding what the price has to be for Medicare to cover these medications.
當然,我的意思是,我不太確定我在這個議題上的看法有多大價值。但你看,我想你我都同意,Medicare必須涵蓋這些藥物;而且我也認為,很可能Medicare與Lilly以及Novo之間,針對Medicare要涵蓋這些藥物所需的價格,已經談判了一段時間。
So I'm extremely optimistic that, at some point in the near future, Medicare is going to cover these drugs. And you're already seeing coverage in some indications like in some cardiovascular, where there's -- for some cardiovascular conditions and also, for instance, obstructive sleep apnea. So I think these things take time. What's important for LifeMD is that we're ready to go the day that there is broad coverage for these medications from Medicare.
所以我非常樂觀地認為,在不久的將來某個時間點,Medicare會涵蓋這些藥物。而且你已經看到在某些適應症上有涵蓋,例如某些心血管——針對某些心血管疾病,以及例如阻塞型睡眠呼吸中止症。所以我認為這些事情需要時間。對LifeMD而言重要的是:在Medicare對這些藥物提供廣泛涵蓋的那一天,我們已經準備就緒。
And our commitment to shareholders and patients is that we're going to be ready, and we're going to have the most comprehensive offering out there for Medicare patients that want to access these drugs. I mean, this is a population that should have access to these drugs and needs these drugs as much or more than anybody else out there. So we're just doing everything we can to make sure that we have the right compliance and operational infrastructure in place to execute the day that this coverage is put in place, which I think is going to be sometime soon.
我們對股東與患者的承諾是:我們會準備好,而且我們將為想要取得這些藥物的Medicare患者,提供市場上最全面的方案。我的意思是,這是一個應該能取得這些藥物、而且對這些藥物的需求不亞於甚至高於其他任何族群的人口。所以我們正在盡一切努力,確保我們具備正確的合規與營運基礎設施,以便在這項涵蓋落地的那一天執行到位;而我認為那會在不久之後的某個時間。
Brooks O'Neil - Analyst
Brooks O'Neil - Analyst
Right. And then is there any update on Medicare reimbursement for the telehealth services?
了解。那麼,關於Medicare對遠距醫療服務的給付,有沒有任何更新?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Yeah, so the current bill that's working its way through the legislature has included telehealth, an extension of telehealth coverage, which I believe it's an extension through the fall of this year. So clearly there's going to still need to be a more permanent solution. But everybody that we've talked to, Brooks, on The Hill is highly confident that you're going to see a permanent extension of Medicare coverage for virtual care and that it has bipartisan support and it's just a matter of working its way through the legislature.
有的,目前正在立法機關推進的法案已經納入遠距醫療,也就是延長遠距醫療涵蓋;我相信是延長到今年秋季。所以很明顯,仍然需要一個更永久的解決方案。但我們在國會山莊(The Hill)與每一位我們談過的人都非常有信心,你將會看到Medicare對虛擬照護的涵蓋永久延長;而且它有兩黨支持,剩下只是立法程序推進的問題。
Brooks O'Neil - Analyst
Brooks O'Neil - Analyst
Sure, makes sense. One last question, I appreciate you taking my questions. I'm excited about the opportunity with behavioral health. Frankly, I'm excited about a lot of opportunities you have, but behavioral health seems like a no brainer. Your combination of Telehealth services, counseling, access to drugs, etcetera.
好的,合理。最後一個問題,感謝你回答我的問題。我對行為健康(behavioral health)的機會感到很興奮。坦白說,我對你們很多機會都很興奮,但行為健康看起來是顯而易見的選擇。你們結合了遠距醫療服務、諮商、用藥取得等等。
Can you just help us be sure we understand the program you envisioned and how do you think it will work for LifeMD and your member patients.
你能否協助我們確認理解:你們所設想的計畫是什麼,以及你認為它將如何為LifeMD與你們的會員患者運作?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Sure, yeah. Thanks, Brooks, for bringing this up because this is something that we're also extremely excited about. Clearly, the behavioral health market is massive. I think in order to have a comprehensive primary care platform, you have to do a great job in behavioral health. You have to offer treatment for behavioral health. So this is something that we've wanted to launch for a while.
當然。謝謝你,Brooks,提出這點,因為這也是我們非常興奮的事情。很明顯,行為健康市場規模巨大。我認為要打造一個全面的初級照護平台,你必須在行為健康方面做得非常出色。你必須提供行為健康的治療。所以這是我們想推出一段時間的項目。
We took a very thoughtful, careful approach to how we entered the space. The big catalyst for us entering it now was finding Julian Cohen, and I would encourage everybody that hasn't already done this to go look at his background. Over the last 30 years, he has run some of the largest behavioral health operations in the country for names like Cigna, Teladoc, HIMSS. I mean, it's wildly impressive background in virtual behavioral health.
我們對如何進入這個領域採取了非常周全、謹慎的方法。我們現在進入的最大催化劑,是找到Julian Cohen;我也鼓勵所有尚未了解的人去看看他的背景。在過去30年裡,他在全國一些最大的行為健康營運中擔任領導角色,服務過像Cigna、Teladoc、HIMSS等機構。我的意思是,他在虛擬行為健康方面的背景非常令人印象深刻。
So we found Julian. He's working on building some of these programs now on the LifeMD platform. We're going to start with an async first offering for anxiety and depression. And we're already talking with some large talk therapy partners as well, because one thing that's very important to us is that we're not just offering kind of async treatment for behavioral health, we're also providing patients at the same time, like an incredible talk therapy solution when that's appropriate.
所以我們找到了 Julian。他現在正在 LifeMD 平台上著手建立其中一些方案。我們將先從以非同步為主的焦慮與憂鬱服務開始。而且我們也已經在和一些大型談話治療合作夥伴洽談,因為對我們來說非常重要的一點是:我們不只是提供某種行為健康的非同步治療,同時也會在適當的情況下,為病患提供非常出色的談話治療解決方案。
And behind that, I think the sky is the limit, right? I mean, there's a number of big, virtual behavioral health markets where there's a large unmet clinical need that I think is going to be very good for patients out there, and extremely good for our shareholders.
而在這之後,我認為前景無可限量,對吧?我的意思是,虛擬行為健康市場中有好幾個大型領域存在大量未被滿足的臨床需求,我認為這對外面的病患會非常有利,也會對我們的股東極為有利。
Brooks O'Neil - Analyst
Brooks O'Neil - Analyst
Great, thanks. I'll follow up more later on, but I'm excited about that.
很好,謝謝。我稍後會再追問更多,但我對此感到很興奮。
Operator
Operator
Steven Valiquette, Mizuho Securities.
Steven Valiquette,瑞穗證券。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Let me offer my congrats on the results as well. Really the questions I have, just a couple kind of intertwined, really around what's embedded within the 2025 revenue guidance, especially within the telehealth segment? And if you disclosed previously that over 70% of the weight loss management patients were on compounded semaglutide as you were exiting '24.
我也先恭喜你們的業績表現。我主要有幾個彼此相關的問題,想了解 2025 年營收指引中所隱含的假設,特別是在遠距醫療(telehealth)部門裡?另外,如果你們先前揭露過,在 2024 年結束時,超過 70% 的體重管理病患使用的是複方司美格魯肽(compounded semaglutide)。
So I guess what does your '25 revenue guidance imply for percentage retention of these patients? I'm guessing most of them just based on how strong the guidance is. And what should -- I mean, do you have just assumptions in there for what the conversion rates will be whether they switch to brands? Do they switch to you, or do you think they'll stay on the compounded versions because of the personalized dose that we talked about? Just curious to get more color on all the assumptions within the revenue guidance.
所以我想問的是,你們的 2025 年營收指引對這些病患的留存比例意味著什麼?我猜大多數都會留存,因為指引看起來很強勁。那麼你們在裡面是否有對轉換率做假設——例如他們是否會轉用品牌藥?他們是轉到你們這邊,還是你們認為他們會因為我們談到的個人化劑量而繼續使用複方版本?想更了解營收指引中各項假設的細節。
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
I believe we've said before and we've discussed with some investors, we produced our planning and our guidance for next year. We took a pretty significant writedown on the compounded medication in there. We actually basically wrote off something close to half of it. Obviously, we assumed a certain percentage of that would go over to branded therapy.
我相信我們之前說過,也和一些投資人討論過:我們在制定明年的規劃與指引時,已經對複方藥品做了相當大幅度的減記。實際上我們基本上沖銷了接近一半。當然,我們也假設其中一定比例會轉向品牌療法。
There are no assumptions that the rate of growth and new acquisitions is going to improve. As a matter of fact, the actual guidance assumes that it's going to be a little bit lower than what it was last year. It assumes that there will be some that will try it out. We don't give out the exact percentage because we haven't necessarily put that in publicly. And then we also had some write-off related to compound subscribers.
我們並沒有假設成長率與新客獲取會改善。事實上,指引假設它會比去年略低一些。我們假設會有一部分人會去嘗試。我們不會提供確切百分比,因為我們不一定已經在公開場合披露該數字。此外,我們也針對複方訂閱用戶做了一些沖銷。
Now the goal for us is to get to about 40% to 50% patients on branded therapy by the end of the year. Obviously, we think that there will be some personalized, certainly some triple therapy as well, but we're not banking on retaining tons of patients within compounded therapy.
目前我們的目標是在年底前,讓約 40% 到 50% 的病患使用品牌療法。當然,我們認為會有一些個人化方案,肯定也會有一些三重療法(triple therapy),但我們並沒有把大量留在複方療法的病患留存作為主要依據。
As a matter of fact, we wrote off a lot of that and assumed a lot of the growth will come in from new patients going on to branded therapy, as well as the fact that, I mean, let's not forget here that there's an awful lot of competitors out there that all they do is compound the therapy and can't do anything else or their business is set up just to make money off of selling the compound product whereas our business is set up as a service business that seeks to provide access for patients.
事實上,我們已經沖銷了其中很大一部分,並假設相當多的成長將來自新病患開始使用品牌療法;同時也別忘了,市場上有非常多競爭者,他們所做的就只是複方配製療法,除此之外做不了別的,或是他們的商業模式就是靠賣複方產品賺錢;而我們的業務定位是一個服務型業務,目標是為病患提供可及性。
All of those negative assumptions are already put in the budget model for next year. Where we're seeing improved performance relative to what I think some folks may have thought is on the direct side. We're obviously seeing strong growth there within the sexual health business. The HRT took us a little bit of time to figure out initially, but we're very optimistic there, and retention should be very strong within that business.
所有這些偏負面的假設都已經納入明年的預算模型。相較於我認為部分人士原先的預期,我們看到表現有所改善的地方是在直營端(direct side)。我們在性健康業務方面顯然看到強勁成長。HRT 一開始花了我們一些時間摸索,但我們對那塊非常樂觀,而且該業務的留存應該會非常強。
Behavioral health was something that until recently wasn't fully on the roadmap, so we expect to get some incremental benefits this year on that. And then obviously the relaunch of primary care and revamped LifeMDPlus primary care has a small amount of incremental benefits in there.
行為健康直到最近才沒有完全納入路線圖,因此我們預期今年在那方面會帶來一些增量效益。另外,初級照護(primary care)的重新上線,以及改版後的 LifeMDPlus 初級照護,也會帶來少量的增量效益。
Operator
Operator
Alex Fuhrman, Craig Hallum Capital Group.
Alex Fuhrman,Craig Hallum Capital Group。
Alex Fuhrman - Analyst
Alex Fuhrman - Analyst
Justin, I'd love to talk more about the hormone therapy offering that you launched recently for RexMD. Curious if you can share how many patients you currently have taking advantage of that offering. And then the guidance for this year, obviously very strong on both the top and bottom line. Is hormone therapy expected to be a pretty big contributor this year. I imagine that could be a huge opportunity longer term, but curious what you have kind of pencilled in for this year for that offering.
Justin,我很想多聊聊你們最近為 RexMD 推出的荷爾蒙療法服務。想請問目前大概有多少病患正在使用這項服務?另外,今年的指引在營收與獲利端都非常強勁。荷爾蒙療法預期會是今年相當大的貢獻來源嗎?我想長期來看這可能是很大的機會,但也想了解你們今年對這項服務大概預估了多少。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
So I guess, first of all, we've been very pretty conservative with our growth estimates for that business for 2025, although I will say that we're incredibly optimistic about the prospects for the HRT business both for men and for women.
我想,首先,我們對 2025 年該業務的成長預估一直相當保守;不過我也要說,我們對 HRT 業務(不論男性或女性)的前景極度樂觀。
But on the Rex side, I mean, I think we talked about this concept a lot over some of the past earnings costs, but for many of the men that are accessing this program, it's the best healthcare they've ever received in their life. They're 100% of people in order to access any of the therapy are going to question the lab core they're having a lab panel done that would cost, anywhere between $1000 and $1500.
但在 Rex 這邊,我的意思是,我想我們在過去幾次財報電話中談過這個概念:對許多使用這個方案的男性而言,這可能是他們一生中接受過最好的醫療照護。為了取得任何療法,100% 的人都會先做一套實驗室檢測(lab panel),其費用大約在 1,000 到 1,500 美元之間。
It's just because it's so comprehensive they're having a call with one of our wellness coordinators in most cases then they're doing a typically a 30-minute video call with a state licensed physician that is specialized in men's health. I think approximately 70% of men that go through all of that are then getting put on a therapy. It's not always testosterone, sometimes it ends up being a GLP-1 there are multiple therapies that can be appropriate, for the patient, depending on their lab work and their symptoms.
這主要是因為檢測非常全面;多數情況下,他們會先與我們的健康協調員通話,接著通常會與一位具州執照、專精男性健康的醫師進行約 30 分鐘的視訊看診。我認為大約有 70% 的男性完成這些流程後會被安排接受某種療法。不一定都是睪固酮,有時最後會是 GLP-1;可能適合病患的療法有多種,取決於他們的檢驗結果與症狀。
But from a quality of revenue standpoint, Alex, we are so excited about this business, right? And it's quality of -- I mean I'll emphasize; I already did emphasize quality of care is incredible, but quality of revenue as well as we think is going to be incredible. CPAs are very encouraging, we're, we, we're not going to share an exact patient number today, but I will tell you that we've gotten this business to a point where we see a clear pathway to a couple hundred patients a day.
但從營收品質的角度來看,Alex,我們對這項業務非常興奮,對吧?而且是品質的——我的意思是,我會強調:我已經強調過照護品質非常出色,但我們也認為營收品質同樣會非常出色。CPA(每次獲客成本)數據非常令人鼓舞;我們今天不會分享確切的病患數,但我可以告訴你,我們已經把這項業務推進到一個階段:我們看到每天做到數百名病患的清晰路徑。
And you know if we could do that. I mean that means that business could be just as big as our ED business or our entire RexMD business today. Yeah, so and then and they clearly like look that's a very bullish statement, but one of the great things about our business is, it's very predictable and we know once we see CPAs that we know when we when we get to kind of a CPA and a conversion rate that is highly scalable in a large market like this, and we are extremely confident this is scalable.
而你知道,如果我們能做到那樣,我的意思是,那代表這項業務的規模可能會和我們的 ED 業務一樣大,或甚至和我們目前整個 RexMD 業務一樣大。是的,所以——而且很明顯,這聽起來是非常看多的說法;但我們業務的一個優點是,它非常可預測。我們一旦看到 CPA,就能知道:當我們達到在這樣一個大型市場中可高度擴張的 CPA 與轉換率時,我們就會非常有信心它是可規模化的,而我們對此極具信心。
On the female side, Alex, we're doing some really exciting things in the women's health world. This is a no-brainer considering that 75% of the patients on our virtual primary care and weight loss programs today are women. It's the perfect cross-care program. We know there's a big demand for it there.
在女性端方面,Alex,我們在女性健康領域正在做一些非常令人振奮的事情。考量到目前我們的虛擬基層醫療與減重計畫中有 75% 的患者是女性,這其實是不言而喻的。這是一個完美的跨照護計畫。我們知道那裡有很大的需求。
And we're working on standing up that program, in the call we mentioned the second half of the year could even be a little bit sooner than that. But one other thing I'll mention before I stop talking is we've now gotten our technology at LifeMD to the point where we can easily launch these programs that are extremely comprehensive, and then scale them and I think that's a really big milestone for us, right?
而我們正在著手把那個計畫建置起來;在電話會議中我們提到可能會在今年下半年,甚至可能比那更早一些。不過在我停止發言前還想補充一點:我們現在已經把 LifeMD 的技術推進到一個程度,能夠很容易地推出這些極其全面的計畫,然後再把它們規模化;我認為這對我們來說是一個非常重要的里程碑,對吧?
It was only a couple of years ago when we had a couple thousand patients on this platform and you know we've just really now built the infrastructure through this weight management offering like and developed the tech to a certain point where we can, quickly and efficiently launch, these new care offerings that are that are great cross care offerings as well. And so I think that's something that we really want investors to understand and and look forward to.
就在幾年前,我們在這個平台上只有幾千名患者;而現在我們透過這個體重管理產品真正建立起基礎設施,並把技術發展到一定程度,使我們能夠快速且有效率地推出這些新的照護服務,而這些也都是很棒的跨照護服務。因此我認為這是我們非常希望投資人能理解並期待的事情。
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
And now one thing I'll add, I mean, as far as our guidance, the male hormone business only assumes a few million dollars in revenue this year, which would be a fraction of the number of new patient per day achieved this year that obviously Justin and the team thinks that we can get to so I think we took a pretty conservative approach there and if we execute depending upon the level that we execute at which we're very confident then there could definitely be upside as in relation to that.
另外我再補充一點:就我們的財測指引而言,男性荷爾蒙業務今年只假設有幾百萬美元的營收,這將只是今年每日新增患者數所能達到水準的一小部分;而 Justin 和團隊顯然認為我們可以做到那個水準。所以我認為我們在這裡採取了相當保守的做法;若我們能執行到位——而我們對此非常有信心——那麼相對於這部分確實可能會有上行空間。
Alex Fuhrman - Analyst
Alex Fuhrman - Analyst
Terrific, guys, that sounds all like good news appreciate the thorough response from both of you.
太棒了,各位,聽起來都是好消息,感謝你們兩位詳盡的回覆。
Operator
Operator
Sarah James, Cantor.
Sarah James,Cantor。
Sarah James - Analyst
Sarah James - Analyst
Thank you and congrats on a fantastic quarter. I wanted to unpack the EBITDA guidance a little bit. It's up $15 million at the midpoint, and we're estimating, we're simply now that it's back to $1 million a month. It could be 5 of that. And the gross margin improvement another about $1 million, but that's still leaves $9 million improvement.
謝謝,也恭喜你們交出非常出色的一季。我想更深入拆解一下 EBITDA 指引。以中位數來看上調了 1,500 萬美元,而我們估算——我們只是——現在它回到每月 100 萬美元。其中可能有 500 萬美元來自那部分。再加上毛利率改善約 100 萬美元,但這樣仍然還剩下 900 萬美元的改善。
How much that is growth in your core business versus non-repeat of costs like the compliance of setting up an insurance or other aspects that could fall below the gross margin line and then do you have any assumption of earnings contribution from the new segments?
其中有多少是核心業務成長帶來的, versus 不會重複發生的成本(例如設立保險相關合規成本)或其他可能落在毛利線以下的項目?另外,你們是否假設新業務板塊會有任何獲利貢獻?
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
Yeah, so it's Marc. So firstly, I mean the way the guidance breaks down is approximately $20 million from Telehealth, $10 million to $12 million from work simply, the increase in even does essentially growth in the business, there's not a lot of cost structure. With that business outside of ad spend and payroll, so most of that is associated with growth, on the telehealth side also the majority of it is associated with growth. I mean the category of non-repeated expense. I mean, yes, there were some initial costs associated with pharmacy set up and some compliance and other things.
好的,我是 Marc。首先,指引的拆解大約是:Telehealth 約 2,000 萬美元,WorkSimpli 約 1,000 萬到 1,200 萬美元;EBITDA 的提升基本上就是業務成長帶來的,因為那個業務的成本結構不多。除了廣告投放與薪資之外,所以大部分都與成長相關;在 Telehealth 端也是,多數同樣與成長相關。至於不會重複的費用類別,是的,確實有一些與藥局設立、合規以及其他事項相關的初期成本。
But that's essentially around a million dollars of things that. Kind of go by the wayside because new costs do get introduced, as certain parts of those, segments get larger that didn't previously, exist on an ongoing basis. So a lot of that also comes down to growth, gross margin, gross profit, we expect to be somewhat similar on a margin rate basis to what it was for the full year of 2024.
但那大致上約 100 萬美元,屬於會逐步消失的項目。不過隨著某些業務板塊變大,也會引入新的成本,而這些成本在過去並不存在、但未來會成為持續性支出。因此很多仍然回到成長、毛利率與毛利;我們預期在毛利率(比例)基礎上,會與 2024 全年的水準大致相近。
And the reason for that is, I mean, one, we're expecting to receive approximately $2 million of COGS benefits in relation to the pharmacy that we opened in the fourth quarter. But there are some mixed changes in the business also.
原因是:第一,我們預期會因為第四季開設的藥局而獲得約 200 萬美元的 COGS(銷貨成本)效益。但業務組合也會有一些變化。
So HRT for example, while extremely profitable from a bottom line economic standpoint because of the retention associated with it, which obviously drives a lot of leverage in the ad spend, the pure gross profit, is that the gross margin percentage that is not as high as some of the other businesses because the underlying COGS, are higher, so it'll be an upper-70s, mid- to upper-70s versus, an upper-80s.
例如 HRT,雖然從最終損益的經濟性角度來看非常有利可圖,因為它帶來的留存率——這顯然能在廣告投放上形成很大的槓桿——但就純毛利而言,其毛利率百分比不會像其他一些業務那麼高,因為其底層 COGS 較高;所以毛利率會在 70% 高段、約中到高 70% 的區間,而不是 80% 高段。
But obviously it's very creative to the bottom line of the company. So most of it's going to come from growth in the business, leveraging your sales and marketing spend which will grow up obviously year on year, but it's going to go up by less of a percentage than what the revenue will go up in and then obviously leveraging your G&A, which again is all driven by growth in the company and then you know moderate growth in expenses.
但很明顯它對公司的最終獲利是高度增益的。因此大部分改善將來自業務成長、對銷售與行銷支出的槓桿運用——這些支出當然會年增,但增幅會低於營收增幅——以及對 G&A(一般及行政費用)的槓桿運用;而這同樣都是由公司成長所驅動,並伴隨費用的溫和成長。
Sarah James - Analyst
Sarah James - Analyst
Great. And one more if I could. The new insured lives, both commercial and Medicare, what percent of revenue are you assuming from that group in 25 and where could it go in a couple of years?
很好。如果可以我再問一個。新增的受保人數(商業保險與 Medicare),你們在 2025 年假設該族群貢獻營收的比例是多少?而在未來幾年可能會到什麼程度?
Marc Benathen - Chief Financial Officer
Marc Benathen - Chief Financial Officer
Yeah, I mean it's relatively small what we're assuming in '25 and we're assuming essentially mid-single-digit percentage of total revenue to come from that in '25, as we mentioned before, there's a big ramp up there you can acquire a lot of lives. So it's very important that you know we get to a national presence which on the private insurance side is where we're going to take until like the back half of the latter part of 2025.
是的,我們在 2025 年的假設相對較小;我們基本上假設 2025 年總營收中約有中個位數百分比來自那部分。正如我們之前提到的,那裡有很大的爬坡空間,你可以獲得大量受保人。因此非常重要的是,我們要建立全國性的覆蓋;在私人保險端,我們預計要到 2025 年後半段的較後期才會達成。
And you have a lot of people that are essentially paying a small platform fee per month, $19 per month. Which is where obviously most of the margin comes from that business and then insurance reimbursements, which, are also at more moderate levels and obviously the cash pay business. So I don't think it's going to be a huge revenue contributor, but it will gain us a lot of scale where that can go to.
而且會有很多人基本上每月支付一筆小的平台費,19 美元/月。這也是該業務大部分毛利的來源;另外還有保險給付(reimbursements),其水準也較為溫和,以及當然還有自費(cash pay)業務。所以我不認為它會是非常大的營收貢獻者,但它會讓我們獲得很大的規模,並為未來成長打下基礎。
I mean, it could easily within the next three to four years being in the range of 30% to 50% of the revenue because you start to get this snowball effect as you acquire a bunch of subscribers and it's particularly relevant to the LifeMD Plus offering which again we're just, launching the revamped version in Q2 and that's going to start to scale from there which also will take some time, but it's not a major, driving factor in anything that we have in the guidance, in 2025. Thank you.
我的意思是,在接下來三到四年內,它很容易可以達到營收的 30% 到 50% 區間,因為當你累積大量訂閱者後會出現雪球效應;這對 LifeMD Plus 產品尤其相關——我們將在第二季推出改版後的版本,之後會開始擴大規模;這也需要一些時間,但在我們 2025 年的指引中,它並不是任何項目的主要驅動因素。謝謝。
Operator
Operator
Anderson Schock, B. Riley Securities.
Anderson Schock,B. Riley Securities。
Anderson Schock - Analyst
Anderson Schock - Analyst
Hi, congrats on the great quarter and thank you for taking the questions. So first, on the weight management business, what percentage of your new patients are getting insurance approvals for the branded therapies now following your investment and enhancing your insurance infrastructure?
嗨,恭喜你們交出很棒的一季,也謝謝你們回答問題。首先,關於體重管理業務,在你們投資並強化保險基礎設施之後,目前新患者中有多少比例能為品牌療法取得保險核准?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
So the way the numbers, this is Justin speaking by the way, so the way the numbers break down is around 10% of patients are receiving coverage, for obesity, off the bat, without us filing a prior authorization.
我先說明一下數字的拆解——順帶一提我是 Justin——大約有 10% 的患者在一開始就能獲得肥胖治療的保險給付,而不需要我們提交事前授權(prior authorization)。
Approximately 60% of patients that have private insurance are required to, are getting a response that requires them to file a prior authorization. And as we said on the call, about 60% of about 60% of the prior authorizations that we're filing right now for that bound for patients that are obese, I mean they have a 30 BMI or higher, are getting really affordable coverage for the drug.
大約有 60% 擁有私人保險的患者會被要求——也就是收到回覆表示需要提交事前授權。而正如我們在電話會議中所說,我們目前為符合條件的肥胖患者(也就是 BMI 30 以上)所提交的事前授權中,大約有 60% 能夠獲得該藥物非常可負擔的保險給付。
Anderson Schock - Analyst
Anderson Schock - Analyst
Okay, got it. And are you seeing existing subscribers who previously or currently are using the compounded therapies now being able to obtain approval and switch to the branded GLP-1?
好的,了解。那您是否看到先前或目前正在使用複方療法的既有訂閱者,現在能夠取得核准並轉換到品牌的 GLP-1?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
We are seeing some of that and it's something that we do is we rerun benefits regularly for patients that are on compounded therapies. I don't have a number to share with you on that, but it is something that, we do see on a regular basis and it's a priority for us to continue to run benefits for patients that are on a compounded therapy.
我們確實看到一些這樣的情況,而我們也會定期為使用複方療法的患者重新跑一次保險給付資格。我沒有可與您分享的具體數字,但這確實是我們經常看到的情況,我們也將持續為使用複方療法的患者進行給付資格查核視為優先事項。
Anderson Schock - Analyst
Anderson Schock - Analyst
Okay, got it. And with the FDA set to crack down on compounding pharmacies and outsourcing facilities in April and May, do you plan to continue connecting patients with compounded GLP-1 until then?
好的,了解。另外,FDA 預計在 4 月與 5 月加強打擊複方藥局與外包製造設施,在那之前你們是否計畫繼續協助患者取得複方 GLP-1?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
We plan to continue, we plan to continue to follow the guidance of our kind of inside and outside legal advisors as well as the FDA. I mean, our position is the same as it's always been. We think there has to be an affordable route to patients accessing these medications. There are many Americans still can't afford $500, $600, $700 a month for a weight loss medication.
我們計畫繼續,我們計畫繼續遵循我們內部與外部法律顧問以及 FDA 的指引。我的意思是,我們的立場一如既往。我們認為患者必須有一條可負擔的途徑來取得這些藥物。仍有許多美國人無法負擔每月 500、600、700 美元的減重藥物費用。
So whether that ends up being a personalized version of a compounded drug that doesn't violate the intellectual property, of one of the manufacturers, I mean, that may be a viable route, but we're committed to doing whatever, we're committed to putting patients first, which is what we've done since day one.
因此,不論最後是否會是某種客製化的複方藥版本、且不侵犯某家製造商的智慧財產權,我的意思是,那可能是一條可行的路徑;但我們承諾會做任何該做的事,我們承諾以患者為先,這也是我們從第一天起就一直在做的。
And we continue to believe that the FDA and the federal government are not going to strip access to these medications from Americans that can't afford them just because they don't have blue chip insurance coverage. So it's an evolving landscape. Again, we, we've always operated kind of very conservatively in the space. And we're going to continue to follow the lead of, the FDA and again of our legal advisors and, do what's best for patients.
我們也持續相信,FDA 與聯邦政府不會僅因為這些美國人沒有頂級的保險保障,就剝奪他們取得這些藥物的機會。所以這是一個持續演變的環境。再次強調,我們在這個領域一向採取相當保守的做法。我們將繼續遵循 FDA 的方向,以及我們法律顧問的建議,並做出對患者最有利的決定。
Anderson Schock - Analyst
Anderson Schock - Analyst
Okay, got it. Great, well thank you for taking our questions.
好的,了解。很好,謝謝你們回答我們的問題。
Operator
Operator
Yi Chen, HC Wainwright.
Yi Chen,HC Wainwright。
Unidentified Participant
Unidentified Participant
Hi, good afternoon, this is Eduardo on for Yi. Just had one question kind of in a different vein. You had mentioned previously some development in the context of monitoring and possibly collaborating. I was just kind of curious if you had any catalyst in 2025 to look for remote monitoring with wearables or anything like that or any developments in that space we can expect over the next year.
嗨,午安,我是 Eduardo,代 Yi 發言。我只有一個問題,方向有點不同。你們先前提到在監測以及可能合作方面的一些進展。我想請教一下,2025 年在穿戴式裝置的遠端監測或類似領域,是否有任何可期待的催化劑,或未來一年在這方面會有哪些進展?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Yeah. Thanks for the question. You know what we're one of the things that's been on our priority list for a while has been integrating wearables into the LifeMD mobile application. We currently have scales that we ship out to some of our weight management patients they have a lot of different kind of metabolic measurements, they generate and are organized on our platform and shared with patients' providers.
是的。謝謝你的提問。你知道,我們優先事項清單上有一項已經放了一段時間,就是把穿戴式裝置整合進 LifeMD 行動應用程式。我們目前會寄送體重計給部分體重管理患者;這些體重計可產生多種代謝相關量測數據,並在我們的平台上彙整,且與患者的醫療提供者共享。
As far as far as LifeMD doing more in the remote patient monitoring world. It's not something that we have on the road map for 2025.
至於 LifeMD 在遠端病患監測(RPM)領域做更多事情,這不在我們 2025 年的規劃路線圖上。
Unidentified Participant
Unidentified Participant
Okay, totally understand. And anything in the, I know you guys are also working in the space of at home diagnostics, so that any developments in that space?
好的,完全理解。另外,在……我知道你們也在居家診斷領域努力,所以那方面有任何進展嗎?
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Sure we're working on a lot in that space. I mean we're constantly evaluating a lot of the you know in home collection devices that are out there. There two or three that are certainly very interesting to us. The amount of blood that you can collect with many of those devices is, it's limited, so like to run a kind of more comprehensive lab panel for something like our hormone therapy offering.
當然,我們在那個領域做了很多工作。我的意思是,我們一直在評估市面上的各種居家採樣裝置。其中有兩到三種確實讓我們非常感興趣。但許多裝置可採集的血量有限,因此若要針對例如我們的荷爾蒙療法服務,進行較全面的檢驗面板,
You would need multiple devices, which is a really negative experience for patients. We are working with some of the in-home phlebotomy companies as well as Quest and Labcorp, which both have in-home phlebotomy options to make like blood collection more convenient for our HRT patients.
你就需要多個裝置,這對患者而言是非常不好的體驗。我們正與一些到府抽血(in-home phlebotomy)公司合作,也與 Quest 和 Labcorp 合作;這兩家公司都有到府抽血選項,以讓我們的 HRT 患者採血更便利。
But look at the space we're really excited about. I think that being able to collect like sufficient blood remotely from patients to run panels, like, for instance, the hormone panel. It's really important for our business, right? I mean, lab work is important for a lot of the care programs and medication offerings at LifeMD and so we're really evaluating the space and we think it's a space where there's going to be a lot of innovation in the near future.
不過你看,這個領域我們真的很興奮。我認為,能夠從患者端遠端採集足夠的血量來跑檢驗面板,例如荷爾蒙面板,對我們的業務非常重要,對吧?我的意思是,檢驗對 LifeMD 許多照護計畫與用藥服務都很重要,因此我們正在深入評估這個領域,也認為在不久的將來會有大量創新出現。
Unidentified Participant
Unidentified Participant
Wonderful. Thanks for the answer to the question.
太好了。謝謝你的回答。
Operator
Operator
And with no other further questions at this time, I will turn the call back over to Mr. Schreiber for any additional or closing remarks.
目前沒有其他問題,我將把電話交回給 Schreiber 先生,請他做任何補充或結語。
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Justin Schreiber - Chairman of the Board, Chief Executive Officer
Thank you, everyone, for your questions and for your interest in LifeMD. We look forward to speaking with you once again when we report our first quarter results in May. Have a great evening.
謝謝各位的提問,以及對 LifeMD 的關注。我們期待在 5 月公布第一季業績時,再次與各位交流。祝各位晚安。
Operator
Operator
Thank you, ladies and gentlemen, this will conclude today's program. We thank you for your participation. You may disconnect at any time.
謝謝各位女士先生,今天的會議到此結束。感謝各位的參與。您可隨時掛線。